Literature DB >> 30133068

Encephalitis is an important clinical component of myelin oligodendrocyte glycoprotein antibody associated demyelination: a single-center cohort study in Shanghai, China.

L Wang1, J ZhangBao1, L Zhou1, Y Zhang1, H Li2, Y Li2, Y Huang3, M Wang3, C Lu1, J Lu1, C Zhao1, C Quan1.   

Abstract

BACKGROUND AND
PURPOSE: Besides a distinct spectrum of demyelinating syndromes, encephalitis was observed in patients with myelin oligodendrocyte glycoprotein antibodies (MOG-abs).
METHODS: The clinical records of 690 patients with idiopathic demyelinating diseases of the central nervous system seen in our center from June 2015 to December 2017 were retrospectively reviewed. All underwent serum aquaporin 4 antibody (AQP4-ab) and MOG-ab detection by cell-based assays as a routine diagnostic approach. Patients with MOG-abs or AQP4-abs who had ever experienced an encephalitis-like illness during the disease course were identified. Whether diagnoses of possible or definite autoimmune encephalitis could be reached with regard to these particular episodes of encephalitis was determined. The incidence and clinical features of encephalitis in anti-MOG disease are described in detail and compared with those in anti-AQP4 disease.
RESULTS: Amongst the 690 patients, 87 were MOG-ab-positive whilst 140 were AQP4-ab-positive. 20.7% (18/87) of the MOG-ab-positive patients had typical presentations of encephalitis. Unique cortical lesions (72.2%, 13/18) were observed; fever (55.6%), intracranial hypertension (41.2%) and cerebrospinal fluid pleocytosis (64.7%) were common during MOG-ab-associated encephalitis. Sixteen of the 18 patients fulfilled the criteria of definite autoimmune encephalitis (specific disease with MOG-ab) during encephalitis, and five patients overlapped with anti-N-methyl-d-aspartate-receptor encephalitis (NMDARE). Only 3.6% (5/140) of the AQP4-ab-positive patients had encephalitis, and none overlapped with NMDARE. The Expanded Disability Status Scale scores and the Cerebral Functional System Scores at last follow-up were lower in patients with MOG-ab-associated encephalitis than in those with AQP4-ab-associated encephalitis.
CONCLUSIONS: Encephalitis should be recognized as an important clinical component in anti-MOG diseases.
© 2018 EAN.

Entities:  

Keywords:  N-methyl-d-aspartate receptor; aquaporin 4; encephalitis; myelin oligodendrocyte glycoprotein

Mesh:

Substances:

Year:  2018        PMID: 30133068     DOI: 10.1111/ene.13790

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  22 in total

Review 1.  MOG antibody-associated encephalomyelitis/encephalitis.

Authors:  Sara Salama; Majid Khan; Santiago Pardo; Izlem Izbudak; Michael Levy
Journal:  Mult Scler       Date:  2019-03-25       Impact factor: 6.312

2.  Unilateral cortical FLAIR-hyperintense Lesions in Anti-MOG-associated Encephalitis with Seizures (FLAMES): characterization of a distinct clinico-radiographic syndrome.

Authors:  A Budhram; A Mirian; C Le; S M Hosseini-Moghaddam; M Sharma; M W Nicolle
Journal:  J Neurol       Date:  2019-06-26       Impact factor: 4.849

3.  Recurrent bilateral cortical encephalitis in an adult patient: a case report of delayed diagnosis of myelin oligodendrocyte glycoprotein immunoglobulin G-associated disease.

Authors:  Wan Wang; Juntao Yin; Shaohua Yin
Journal:  J Neurol       Date:  2022-06-29       Impact factor: 6.682

4.  COVID-19 Vaccine-A Potential Trigger for MOGAD Transverse Myelitis in a Teenager-A Case Report and a Review of the Literature.

Authors:  Cristina Oana Mărginean; Lorena Elena Meliț; Maria Teodora Cucuiet; Monica Cucuiet; Mihaela Rațiu; Maria Oana Săsăran
Journal:  Children (Basel)       Date:  2022-05-06

Review 5.  Clinical features and management of coexisting anti-N-methyl-D-aspartate receptor encephalitis and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis: a case report and review of the literature.

Authors:  Di Nan; Ying Zhang; Jinming Han; Tao Jin
Journal:  Neurol Sci       Date:  2021-01-07       Impact factor: 3.307

6.  Anti-MOG associated disease with intracranial hypertension after COVID-19 vaccination.

Authors:  Lina Jeantin; Adèle Hesters; Dorine Fournier; Bénédicte Lebrun-Vignes; Aurélie Méneret; Caroline Papeix; Valérie Touitou; Elisabeth Maillart
Journal:  J Neurol       Date:  2022-04-23       Impact factor: 6.682

7.  Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort.

Authors:  Helen Cross; Farahna Sabiq; Nathalie Ackermans; Andrew Mattar; Shelly Au; Mark Woodhall; Bo Sun; Virginia Devonshire; Robert Carruthers; Ana Luiza Sayao; Virender Bhan; Alice Schabas; Jillian Chan; Marvin Fritzler; Patrick Waters; Anthony Traboulsee
Journal:  Front Neurol       Date:  2021-01-12       Impact factor: 4.003

8.  Anti-Myelin Oligodendrocyte Glycoprotein Antibody-Positive Encephalitis with Seizure and Unilateral Cortical Fluid-Attenuated Inversion Recovery-Hyperintense Lesions.

Authors:  Ki Hoon Kim; Jinhyuk Cho; Kyoo Ho Cho; Ha Young Shin; Seung Woo Kim
Journal:  J Clin Neurol       Date:  2021-07       Impact factor: 3.077

9.  The Clinical Features of FLAIR-Hyperintense Lesions in Anti-MOG Antibody Associated Cerebral Cortical Encephalitis with Seizures: Case Reports and Literature Review.

Authors:  Yun-Feng Wang; Xue-Wu Liu; Jian-Ming Lin; Ji-Ye Liang; Xiu-He Zhao; Sheng-Jun Wang
Journal:  Front Immunol       Date:  2021-06-11       Impact factor: 7.561

10.  Anti-NMDA receptor encephalitis concomitant with myelin oligodendrocyte glycoprotein antibody diseases: A retrospective observational study.

Authors:  Li Du; Huabing Wang; Heng Zhou; Haoxiao Chang; Yuzhen Wei; Hengri Cong; Wangshu Xu; Yuetao Ma; Tian Song; Xinghu Zhang; Linlin Yin
Journal:  Medicine (Baltimore)       Date:  2020-07-31       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.